V-Bio, Gimv lead €37M Camel-IDS series A

Camelid-derived antibody company Camel-IDS N.V. (Brussels, Belgium) raised €37 million ($41.7 million) in a series A round Nov. 15 to support Phase II trials of lead brain metastatic breast cancer candidate, CAM-H2. V-Bio Ventures and Gimv led the round, which included co-lead investors HealthCap Advisor AB, Novo Seeds, Pontifax and BioMedPartners.

Camel-IDS CEO Ruth Devenyns told BioCentury that CAM-H2, a radiolabeled camelid single-domain antibody targeting HER2, can enter brain lesions, unlike mAbs...